Showing 5531-5540 of 5643 results for "".
- RETINA-AI Releases the First Artificial Intelligence Mobile App for Eye Care Providershttps://modernod.com/news/retina-ai-releases-the-first-artificial-intelligence-mobile-app-for-eye-care-providers/2480018/RETINA-AI has developed and released the first artificial intelligence mobile app for eye care providers. The app, called Fluid Intelligence by RETINA-AI, detects macular edema and subretinal fluid on OCT retinal scans with greater than 90% accuracy, according to a company news release. Fl
- American Academy of Optometry Announces 2018 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2018-award-recipients/2480026/Each year the American Academy of Optometry recognizes distinguished individuals who have made countless important contributions to advancing the profession of optometry. “Every nominee represents exactly what the American Academy
- Some AMD Patients May Not Respond to Intravitreal Aflibercepthttps://modernod.com/news/some-amd-patients-may-not-respond-to-intravitreal-aflibercept/2480030/Although intravitreal aflibercept is effective in the great majority of treatment-naive cases of neovascular age-related macular degeneration (AMD), the drug may not work for a small subgroup of patients with choroidal vascular hyperpermeability, Japanese researchers say, according to a
- Some Companies Cancel, Reduce Planned Price Hikes Amid Continued Pressure Over US Drug Costs: Reporthttps://modernod.com/news/some-companies-cancel-reduce-planned-price-hikes-amid-continued-pressure-over-us-drug-costs-report/2480031/Novartis, Gilead Sciences, Roche, and Novo Nordisk have advised California health plans in recent weeks that the companies are rescinding or reducing previously announced price increases on at least 10 drugs, Bloomberg reported Tuesday. The moves come after California introduced legislation earli
- EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-data-highlighting-yutiq-for-posterior-segment-uveitis-to-be-presented-at-asrs/2480032/EyePoint Pharmaceuticals announced that three abstracts supporting the company’s YUTIQ (fluocinolone acetonide intravitreal implant) 3-year micro-insert for noninfectious posterior segment uveitis have been accepted for presentation at the 36th Annual Scientific Meeting of the American Soci
- Oculocare’s Alleye Receives FDA 510(k) Clearance for Monitoring Eyesight in AMDhttps://modernod.com/news/oculocares-alleye-receives-fda-510k-clearance-for-monitoring-eyesight-in-amd/2480036/Oculocare Medical announced the FDA 510(k) clearance of Alleye, a mobile medical software application indicated for the detection and monitoring of age-related macular degeneration (AMD). Alleye is designed to detect and characterize central and paracentral metamorphopsia (visual distortio
- Eyenovia Appoints Michael Rowe as Vice President of Marketinghttps://modernod.com/news/eyenovia-appoints-michael-rowe-as-vice-president-of-marketing/2480038/Eyenovia announced the appointment of Michael Rowe as Vice President of Marketing. Mr. Rowe is a veteran marketing professional with more than 20 years of experience in commercializing products and devices in the United States and globally across the healthcare industry.
- MPOD Measurement Earns American Medical Association CPT III Codehttps://modernod.com/news/mpod-measurement-earns-american-medical-association-cpt-iii-code/2480039/EyePromise announced that on July 1, 2018, macular pigment optical density (MPOD) measurement by heterochromatic flicker photometry has earned a Category III CPT Code from the American Medical Association. While this code does not receive paid reimbursement, Category III CPT Codes are used for da
- Katena Products Announces the Acquisition of Blink Medicalhttps://modernod.com/news/katena-products-announces-the-acquisition-of-blink-medical/2480044/Katena Products announced the purchase of Blink Medical, a UK-based provider of primarily single use ophthalmic instruments. Terms of the deal were not announced. Founded in 2004, Blink Medical currently distributes its products within Europe and the Middle East.
- Lin BioScience Receives EMA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Diseasehttps://modernod.com/news/lin-bioscience-receives-ema-orphan-drug-status-for-lbs-008-for-the-treatment-of-stargardt-disease/2480056/Lin BioScience announced that the European Medicines Agency has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children